| abstract |
The present invention is for use in a method of treating cancer expressing a TLR3 receptor, a double-stranded RNA (dsRNA) has two complementary strands, and comprises at least one block of poly A and a complementary block of poly U. And, each strand has a length of 50 to 200 bases, preferably 55 to 200 bases in length of a double-stranded RNA (dsRNA), and a pharmaceutically acceptable vehicle, carrier, or excipient. will be. |